Charité – Universitätsmedizin Berlin
Berlin, Germany
Team details appear once the team leader joins.
Is this your team? Claim it
Myasthenia gravis
FollowWhat is new in Myasthenia gravis research, which clinical trials are open, and who works on it. From public registries and PubMed, with the source and date of every fact.
Cure status
- addition of rituximab if recurrencePhase 3 · NCT06342544
- ALXN1720Phase 3 · NCT05556096
- CemdisiranPhase 3 · NCT05070858
- Cladribine High DosePhase 3 · NCT06463587
- Cladribine Low DosePhase 3 · NCT06463587
- ClaseprubartPhase 3 · NCT07647510 · NCT06282159
- Decartes-08Phase 3 · NCT06799247
- EfgartigimodPhase 3 · NCT07217587
- Efgartigimod + ThymectomyPhase 3 · NCT07231523
- efgartigimod administrationPhase 3 · NCT06765161
- Efgartigimod IVPhase 3 · NCT04833894 · NCT07284420 · NCT06298552
- Efgartigimod PH20 SCPhase 3 · NCT06392386 · NCT06558279
- GefurulimabPhase 3 · NCT06607627
- immediate treatment with corticosteroidsPhase 3 · NCT06342544
- IMVT-1402Phase 3 · NCT07039916
- inebilizumabPhase 3 · NCT04524273 · NCT06987539
- Intravenous immunglobulin + ThymectomyPhase 3 · NCT07231523
- IptacopanPhase 3 · NCT06517758
- IV PlaceboPhase 3 · NCT04524273
- NipocalimabPhase 3 · NCT07217587 · NCT05265273 · NCT04951622
- Nipocalimab SC-LIVPhase 3 · NCT04951622
- PozelimabPhase 3 · NCT05070858
- Pozelimab + CemdisiranPhase 3 · NCT05070858
- RavulizumabPhase 3 · NCT05644561 · NCT07596784
- Remibrutinib (Blinded)Phase 3 · NCT06744920
- Remibrutinib (Open Label)Phase 3 · NCT06744920
- RozanolixizumabPhase 3 · NCT07463521 · NCT06540144 · NCT07465289
- TelitaciceptPhase 3 · NCT07249632 · NCT06456580
- ZilucoplanPhase 3 · NCT06055959 · NCT06435312
- Zilucoplan®Phase 3 · NCT07215949
- B007Phase 2/3 · NCT06447597
- BlinatumomabPhase 2/3 · NCT06684184 · NCT06836973
- Efgartigimod IV or Efgartigimod PH20 SCPhase 2/3 · NCT05374590
- KYV-101Phase 2/3 · NCT06193889
- Standard lymphodepletion regimenPhase 2/3 · NCT06193889
- Anti-Thymocyte GlobulinPhase 2 · NCT00716066
- Autologous Hematopoietic Stem Cell TransplantationPhase 2 · NCT00716066
- CarmustinePhase 2 · NCT00716066
- CytarabinePhase 2 · NCT00716066
- Descartes-08Phase 2 · NCT07089121 · NCT04146051
- Efgartigimod AlfaPhase 2 · NCT06221501
- Efgartigimod PH20 SC PFSPhase 2 · NCT07673627
- Empasiprubart IVPhase 2 · NCT07673627 · NCT07284420
- EtoposidePhase 2 · NCT00716066
- MelphalanPhase 2 · NCT00716066
- NMD670Phase 2 · NCT06414954
- Peripheral Blood Stem Cell TransplantationPhase 2 · NCT00716066
- PovetaciceptPhase 2 · NCT07501702
- PrednisonePhase 2 · NCT00716066
- SHR-2173 injectionPhase 2 · NCT07622342
- Syngeneic Bone Marrow TransplantationPhase 2 · NCT00716066
- Tocilizumab Injectable ProductPhase 2 · NCT05067348
- UblituximabPhase 2 · NCT07673744
- AritinerceptPhase 1/2 · NCT07596901
- BAFF-R CARTPhase 1/2 · NCT07022197
- CABA-201Phase 1/2 · NCT06359041
- CNP-106Phase 1/2 · NCT06106672
- IM-101 Part APhase 1/2 · NCT07250750
- IM-101 Part BPhase 1/2 · NCT07250750
- ripertamabPhase 1/2 · NCT07372807
- YTB323Phase 1/2 · NCT06704269
- anito-celPhase 1 · NCT06626919
- Azercabtagene zapreleucel (azer-cel)Phase 1 · NCT06680037
- CC-97540Phase 1 · NCT06220201
- CD19-BCMA Targeted CAR-T Dose 1Phase 1 · NCT06371040
- CD19-BCMA Targeted CAR-T Dose 2Phase 1 · NCT06371040
- CD20/BCMA-directed CAR-T cellsPhase 1 · NCT06249438
- CD20/BCMA-directed CAR-T cells Autologous 2nd generationPhase 1 · NCT07676266
- CizutamigPhase 1 · NCT07215650
- CyclophosphamidePhase 1 · NCT07304154 · NCT06626919 · NCT06220201 · NCT07526493
- Dose level 1 groupPhase 1 · NCT06958939
- Dose level 2 groupPhase 1 · NCT06958939
- Dose level 3 groupPhase 1 · NCT06958939
- Dose level 4 groupPhase 1 · NCT06958939
- EA5Phase 1 · NCT07818291
- FludarabinePhase 1 · NCT07304154 · NCT06626919 · NCT06220201 · NCT07526493
- GC012F injectionPhase 1 · NCT07058298 · NCT06759948
- HBI0101 CARTPhase 1 · NCT07085676
- HN2301 injectionPhase 1 · NCT07556120
- KITE-363Phase 1 · NCT07304154
- SYS6020 injectionPhase 1 · NCT06688435
- universal allogeneic anti-CD19/BCMA CAR T-cellsPhase 1 · NCT06978738
- Universal CD19 CAR-γδT Cell InjectionPhase 1 · NCT07526493
- Universal STAR-T CellPhase 1 · NCT07714798
- CD19-CAR-NK Cells InjectionEarly phase 1 · NCT07243366
- CD19/BCMA-targeted CAR-T cellsEarly phase 1 · NCT07337785
- CT103A cellsEarly phase 1 · NCT04561557
- Cyclophosphamide and fludarabineEarly phase 1 · NCT04561557
- Lymphodepleting ConditioningEarly phase 1 · NCT07337785
- QT-019CEarly phase 1 · NCT07392528
- UCAR T-cellEarly phase 1 · NCT06939166
- UCAR T-cell groupEarly phase 1 · NCT06933563
- Universal BCMA CAR-TEarly phase 1 · NCT06485232
- Universal BCMA CAR-T; Universal CD19 CAR-TEarly phase 1 · NCT06485232
- Universal CD19 CAR-TEarly phase 1 · NCT06485232
Closest to patients
- A Study of Nipocalimab Administered to Adults With Generalized Myasthenia GravisA Study of Nipocalimab Administered to Adults With Generalized Myasthenia GravisUniversity of Southern California · Los Angeles, United States + 101 more hospitalsPhase 3Primary completion 2023
- Myasthenia Gravis Inebilizumab TrialMyasthenia Gravis Inebilizumab TrialViela Bio Investigative Site - 5601 · Copenhagen, Denmark + 100 more hospitalsPhase 3Primary completion 2024
- Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia GravisSafety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia GravisResearch Site · Ciudad de Buenos Aires, Argentina + 123 more hospitalsPhase 3Primary completion 2025
Let us optimize your content
Apply for experimental treatment or a research study
The trial team decides who can take part; your doctor can help you ask.
Distance is calculated in your browser. Your city is not sent to us.
Loading trial sites…
Latest news
Results, new trials and publications, newest first. Every item links to its source.
Results and new studies, newest first, in plain words.
Plain-language summary pending. Original title shown.
Publication
A Case of Concurrent Antiacetylcholine Receptor-Positive Myasthenia Gravis and Anti-HMGCR-Positive Myositis Following Statin Exposure.
A Case of Concurrent Antiacetylcholine Receptor-Positive Myasthenia Gravis and Anti-HMGCR-Positive Myositis Following Statin Exposure.
The Journal of rheumatology
PubMed · PMID 42880895Publication
Atorvastatin-associated neurological adverse events: a disproportionality analysis with adjustment for confounding by indication.
Atorvastatin-associated neurological adverse events: a disproportionality analysis with adjustment for confounding by indication.
Frontiers in medicine
PubMed · PMID 42482918Publication
Association Between Statin Initiation and Myasthenia Gravis Crisis.
Association Between Statin Initiation and Myasthenia Gravis Crisis.
Journal of clinical neurology (Seoul, Korea)
PubMed · PMID 42421402
Find fellow researchers
Groups with active Myasthenia gravis work.
University of North Carolina at Chapel Hill
Chapel Hill, United States
Team details appear once the team leader joins.
Is this your team? Claim it
University of South Florida
Tampa, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Yale University
New Haven, United States
Team details appear once the team leader joins.
Is this your team? Claim it
University of Toronto
Toronto, Canada
Team details appear once the team leader joins.
Is this your team? Claim it
Fondazione IRCCS Istituto Neurologico Carlo Besta
Milan, Italy
Team details appear once the team leader joins.
Is this your team? Claim it
University of Oxford
Oxford, United Kingdom
Team details appear once the team leader joins.
Is this your team? Claim it
Argenx (Belgium)
Ghent, Belgium
Team details appear once the team leader joins.
Is this your team? Claim it
Fudan University
Shanghai, China
Team details appear once the team leader joins.
Is this your team? Claim it
Capital Medical University
Beijing, China
Team details appear once the team leader joins.
Is this your team? Claim it
University Health Network
Toronto, Canada
Team details appear once the team leader joins.
Is this your team? Claim it
University of California, Irvine
Irvine, United States
Team details appear once the team leader joins.
Is this your team? Claim it